Supplemental studies in progress counsel that ARV-825 may also be effective in improving the response to estrogen deprivation (aromatase inhibition), another ingredient of normal of treatment in ER+ breast cancer. Celastrol was determined to be a Myb inhibitor that suppressed C/EBPβ exercise